Poxel (POXEL.PA) Stock Price

Poxel Price

Euronext·CLOSED
0.20EUR+0.0015 (+0.75 %)
Market closed

Revenue has compounded at 68.8% per year over the past 9 years to 6.64 M EUR. Poxel's net margin stands at -275.8%, up from -468.1% several years earlier. Analysts set a median price target of 3.57 EUR, implying 1,671.7% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 2% above its 52-week low.

Poxel stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Poxel over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Poxel stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Poxel's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Poxel Stock Price History
DatePoxel Price
8/13/20260.20 EUR
8/12/20260.20 EUR
8/11/20260.20 EUR
8/10/20260.20 EUR
8/7/20260.20 EUR
8/6/20260.21 EUR
8/5/20260.20 EUR
8/4/20260.20 EUR
7/31/20260.21 EUR
7/30/20260.20 EUR
7/29/20260.20 EUR
7/28/20260.20 EUR
7/27/20260.20 EUR
7/24/20260.20 EUR
7/23/20260.20 EUR
7/22/20260.20 EUR
7/21/20260.20 EUR
7/20/20260.20 EUR
7/17/20260.20 EUR
7/16/20260.20 EUR
7/15/20260.20 EUR
7/14/20260.20 EUR
7/13/20260.20 EUR
7/10/20260.20 EUR
7/9/20260.20 EUR
7/8/20260.20 EUR
7/7/20260.20 EUR
7/6/20260.20 EUR
7/3/20260.20 EUR
7/2/20260.20 EUR
7/1/20260.20 EUR
6/30/20260.20 EUR
6/29/20260.21 EUR
6/26/20260.21 EUR
6/25/20260.21 EUR
6/24/20260.20 EUR
6/23/20260.20 EUR
6/22/20260.20 EUR
6/19/20260.21 EUR
6/18/20260.20 EUR
6/17/20260.20 EUR
6/16/20260.21 EUR
6/15/20260.21 EUR
6/12/20260.21 EUR
6/11/20260.21 EUR
6/10/20260.22 EUR
6/9/20260.22 EUR
6/8/20260.23 EUR
6/5/20260.22 EUR
6/4/20260.22 EUR
6/3/20260.22 EUR
6/2/20260.22 EUR
6/1/20260.23 EUR
5/29/20260.23 EUR
5/28/20260.23 EUR
5/27/20260.23 EUR
5/26/20260.23 EUR
5/25/20260.24 EUR
5/22/20260.23 EUR
5/21/20260.24 EUR
5/20/20260.25 EUR
5/19/20260.25 EUR
5/18/20260.25 EUR
5/15/20260.25 EUR
5/14/20260.25 EUR
5/13/20260.25 EUR
5/12/20260.26 EUR
5/11/20260.26 EUR
5/8/20260.26 EUR
5/7/20260.25 EUR
5/6/20260.26 EUR
5/5/20260.25 EUR
5/4/20260.25 EUR
4/30/20260.26 EUR
4/29/20260.25 EUR
4/28/20260.26 EUR
4/27/20260.27 EUR
4/24/20260.27 EUR
4/23/20260.27 EUR
4/22/20260.28 EUR
4/21/20260.27 EUR
4/20/20260.27 EUR
4/17/20260.28 EUR
4/16/20260.28 EUR
4/15/20260.26 EUR
4/14/20260.26 EUR
4/13/20260.25 EUR
4/10/20260.26 EUR
4/9/20260.26 EUR
4/8/20260.27 EUR
4/7/20260.27 EUR
4/2/20260.28 EUR
4/1/20260.32 EUR
3/31/20260.39 EUR
3/30/20260.23 EUR
3/27/20260.24 EUR
3/26/20260.25 EUR
3/25/20260.24 EUR
3/24/20260.24 EUR
3/23/20260.24 EUR
3/20/20260.25 EUR
3/19/20260.25 EUR
3/18/20260.25 EUR
3/17/20260.25 EUR
3/16/20260.25 EUR
3/13/20260.24 EUR
3/12/20260.25 EUR
3/11/20260.25 EUR
3/10/20260.26 EUR
3/9/20260.25 EUR
3/6/20260.25 EUR
3/5/20260.25 EUR
3/4/20260.25 EUR
3/3/20260.25 EUR
3/2/20260.26 EUR
2/27/20260.27 EUR
2/26/20260.27 EUR
2/25/20260.27 EUR
2/24/20260.27 EUR
2/23/20260.27 EUR
2/20/20260.28 EUR
2/19/20260.27 EUR
2/18/20260.27 EUR
2/17/20260.27 EUR
2/16/20260.28 EUR
2/13/20260.29 EUR
2/12/20260.28 EUR
2/11/20260.28 EUR
2/10/20260.28 EUR
2/9/20260.29 EUR
2/6/20260.31 EUR
2/5/20260.32 EUR
2/4/20260.31 EUR
2/3/20260.35 EUR
2/2/20260.38 EUR
1/30/20260.33 EUR
1/29/20260.40 EUR
1/28/20260.24 EUR
1/27/20260.24 EUR
1/26/20260.23 EUR
1/23/20260.24 EUR
1/22/20260.24 EUR
1/21/20260.24 EUR
1/20/20260.24 EUR
1/19/20260.24 EUR
1/16/20260.24 EUR
1/15/20260.24 EUR
1/14/20260.24 EUR
1/13/20260.24 EUR
1/12/20260.24 EUR
1/9/20260.26 EUR
1/8/20260.25 EUR
1/7/20260.24 EUR
1/6/20260.23 EUR
1/5/20260.23 EUR
1/2/20260.23 EUR
12/31/20250.23 EUR
12/30/20250.23 EUR
12/29/20250.23 EUR
12/24/20250.24 EUR
12/23/20250.24 EUR
12/22/20250.24 EUR
12/19/20250.24 EUR
12/18/20250.24 EUR
12/17/20250.24 EUR
12/16/20250.24 EUR
12/15/20250.25 EUR
12/12/20250.26 EUR
12/11/20250.26 EUR
12/10/20250.23 EUR
12/9/20250.23 EUR
12/8/20250.24 EUR
12/5/20250.23 EUR
12/4/20250.24 EUR
12/3/20250.24 EUR
12/2/20250.24 EUR
12/1/20250.25 EUR
11/28/20250.26 EUR
11/27/20250.26 EUR
11/26/20250.22 EUR
11/25/20250.23 EUR
11/24/20250.23 EUR
11/21/20250.23 EUR
11/20/20250.24 EUR
11/19/20250.25 EUR
11/18/20250.26 EUR
11/17/20250.26 EUR
11/14/20250.27 EUR
11/13/20250.28 EUR
11/12/20250.27 EUR
11/11/20250.26 EUR
11/10/20250.26 EUR
11/7/20250.28 EUR
11/6/20250.23 EUR
11/5/20250.25 EUR
11/4/20250.33 EUR
11/3/20250.33 EUR
10/31/20250.31 EUR
10/30/20250.32 EUR
10/29/20250.33 EUR
10/28/20250.33 EUR
10/27/20250.34 EUR
10/24/20250.33 EUR
10/23/20250.34 EUR
10/22/20250.34 EUR
10/21/20250.32 EUR
10/20/20250.32 EUR
10/17/20250.37 EUR
10/16/20250.39 EUR
10/15/20250.41 EUR
10/14/20250.43 EUR
10/13/20250.43 EUR
10/10/20250.42 EUR
10/9/20250.43 EUR
10/8/20250.41 EUR
10/7/20250.41 EUR
10/6/20250.42 EUR
10/3/20250.42 EUR
10/2/20250.43 EUR
10/1/20250.40 EUR
9/30/20250.35 EUR
9/29/20250.36 EUR
9/26/20250.30 EUR
9/25/20250.31 EUR
9/24/20250.31 EUR
9/23/20250.31 EUR
9/22/20250.31 EUR
9/19/20250.31 EUR
9/18/20250.30 EUR
9/17/20250.31 EUR
9/16/20250.31 EUR
9/15/20250.32 EUR
9/12/20250.32 EUR
9/11/20250.32 EUR
9/10/20250.32 EUR
9/9/20250.33 EUR
9/8/20250.30 EUR
9/5/20250.28 EUR
9/4/20250.30 EUR
9/3/20250.32 EUR
9/2/20250.31 EUR
9/1/20250.31 EUR
8/29/20250.31 EUR
8/28/20250.33 EUR
8/27/20250.31 EUR
8/26/20250.32 EUR
8/25/20250.31 EUR
8/22/20250.32 EUR
8/21/20250.30 EUR
8/20/20250.32 EUR
8/19/20250.35 EUR
8/18/20250.36 EUR
Access this data via the Eulerpool API
Get Free API Key

Poxel Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
26.56 M EUR
-24.67 M EUR
-25.74 M EUR
Jan 1, 2020
6.81 M EUR
-30.54 M EUR
-31.86 M EUR
Jan 1, 2021
13.40 M EUR
-23.08 M EUR
-23.76 M EUR
Jan 1, 2022
674,000.00 EUR
-27.09 M EUR
-31.40 M EUR
Jan 1, 2023
1.98 M EUR
-29.38 M EUR
-35.09 M EUR
Jan 1, 2024
6.64 M EUR
-3.66 M EUR
-18.31 M EUR
Jan 1, 2025 (e)
11.60 M EUR
-10.84 M EUR
-66.66 M EUR
Jan 1, 2026 (e)
39.27 M EUR
-26.55 M EUR
-93.51 M EUR

Poxel Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 15, 2026, 8:05 PM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
201120122013201420152016201720182019202020212022202320242025e2026e
––––––5.0074.0026.006.0013.00–1.006.0011.0039.00
–––––––1,380.00-64.86-76.92116.67––500.0083.33254.55
––––––100.00100.00100.00100.00100.00–300.0050.0050.0050.00
3.003.003.003.003.003.005.0074.0026.006.0013.003.003.003.005.5019.50
-8.00-7.00-7.00-6.00-11.00-24.00-22.0012.00-24.00-30.00-23.00-27.00-29.00-3.00-10.00-26.00
––––––-440.0016.22-92.31-500.00-176.92–-2,900.00-50.00-90.91-66.67
-8.00-7.00-20.00-14.00-12.00-24.00-22.0013.00-25.00-31.00-23.00-31.00-35.00-18.00-66.00-93.00
–-12.50185.71-30.00-14.29100.00-8.33-159.09-292.3124.00-25.8134.7812.90-48.57266.6740.91
17.6312.717.8011.9618.9322.6123.0525.5825.9528.4628.6729.1931.7451.4351.4351.43
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Poxel generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Poxel retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Poxel's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Poxel has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Poxel's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Poxel stock margins

The Poxel margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Poxel. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Poxel.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
100.00 %
-92.90 %
-96.93 %
Jan 1, 2020
100.00 %
-448.71 %
-468.09 %
Jan 1, 2021
99.56 %
-172.28 %
-177.37 %
Jan 1, 2022
0.30 %
-4,018.84 %
-4,658.46 %
Jan 1, 2023
0.05 %
-1,482.94 %
-1,771.33 %
Jan 1, 2024
55.12 %
-55.18 %
-275.84 %
Jan 1, 2025 (e)
55.12 %
-93.41 %
-574.68 %
Jan 1, 2026 (e)
55.12 %
-67.60 %
-238.10 %

Poxel Stock Revenue, EBIT, Earnings per Share

The Poxel earnings per share therefore indicates how much revenue Poxel has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
1.02 EUR
-0.95 EUR
-0.99 EUR
Jan 1, 2020
0.24 EUR
-1.07 EUR
-1.12 EUR
Jan 1, 2021
0.47 EUR
-0.81 EUR
-0.83 EUR
Jan 1, 2022
0.02 EUR
-0.93 EUR
-1.08 EUR
Jan 1, 2023
0.06 EUR
-0.93 EUR
-1.11 EUR
Jan 1, 2024
0.13 EUR
-0.07 EUR
-0.36 EUR
Jan 1, 2025 (e)
0.22 EUR
-0.21 EUR
-1.24 EUR
Jan 1, 2026 (e)
0.73 EUR
-0.52 EUR
-1.74 EUR

Poxel business model & stock analysis

Poxel SA is a biopharmaceutical company focused on developing drugs for the treatment of metabolic disorders, particularly type 2 diabetes. The company was founded in Lyon, France, in 2009. Poxel SA's business model is based on the targeted development of drugs for the treatment of metabolic disorders with high medical demand and large market potential. The company focuses on identifying drug candidates that are highly specific and effective while also having a favorable safety profile. Poxel SA collaborates closely with academic research and the industry to leverage the latest knowledge and technologies in drug development. Over the years, Poxel SA has become a leading company in metabolism medicine, with an extensive product pipeline of promising drug candidates. The product range includes both preclinical and clinical candidates, as well as products in advanced stages of clinical development. One of Poxel SA's main products is Imeglimin, a drug for the treatment of type 2 diabetes. Imeglimin is a new active ingredient that acts on the metabolic disorder in a novel way and improves the body's glucose metabolism. The drug is currently in the final phase of clinical development and has shown promising results in previous studies. Another promising product from Poxel SA is PXL770, a drug for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). PXL770 is a novel active ingredient that acts on the body's AMP-activated protein kinase system and regulates lipid and glucose metabolism. The drug is still in the clinical development phase but has already shown promising results. Another promising product group from Poxel SA are the adenosine monophosphate (AMP) activators, which are also being developed for the treatment of metabolic disorders such as type 2 diabetes and fatty liver disease. The AMP activators act on the body's AMP-activated protein kinase system and regulate lipid and glucose metabolism. Poxel SA also works closely with partners in the pharmaceutical industry to develop and bring innovative drug candidates to the market. The company has partnerships with leading companies such as Sumitomo Dainippon Pharma, Roivant Sciences, and Servier to expand and diversify its product pipeline. Overall, Poxel SA is an emerging company in metabolism medicine, focusing on the development of innovative drugs for the treatment of metabolic disorders. With a strong product pipeline and proven collaboration with academia and the industry, Poxel SA is a promising player in this growing market.

Poxel SWOT Analysis

Strengths

Poxel SA has several strengths that contribute to its success in the market. Firstly, the company has a strong and experienced management team with deep knowledge of the pharmaceutical industry. This allows them to make informed and strategic decisions. Secondly, Poxel SA has a robust pipeline of innovative and potentially groundbreaking drugs, which can provide a competitive edge in the market. Additionally, the company has established strong relationships with key partners and collaborators, enabling them to effectively leverage resources and expertise.

Weaknesses

While Poxel SA has many strengths, it also faces certain weaknesses that need to be addressed. One of the weaknesses is the company's heavy reliance on a limited number of products for revenue generation. This concentration of revenue creates a vulnerability for Poxel SA, as adverse events or market changes related to these products could significantly impact its financial performance. Moreover, Poxel SA has a relatively small market share compared to its competitors, which limits its bargaining power with suppliers.

Opportunities

Poxel SA operates in an industry with several growth opportunities. Firstly, there is a rising global demand for innovative pharmaceuticals, especially in the field of metabolic disorders. Poxel SA can take advantage of this demand by leveraging its expertise and developing effective drugs to address this unmet need. Furthermore, the company can explore partnerships and collaborations to expand its market reach and penetrate new regions. Additionally, advancements in technology and research provide Poxel SA with the opportunity to develop more personalized and targeted therapies, leading to improved patient outcomes.

Threats

Like any other company in the pharmaceutical industry, Poxel SA also faces threats that could impact its future growth and profitability. One of the major threats is the stringent regulatory environment, which can delay the approval and commercialization of new drugs. Additionally, the industry is highly competitive, with numerous companies vying for market share. This intensifies the need for Poxel SA to continuously innovate and differentiate its products. Economic downturns and fluctuations in currency exchange rates can also pose threats to the company's financial stability.

Poxel Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Poxel historical P/E ratio, EBIT multiple, and P/S ratio

Poxel annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Poxel shares outstanding

The number of shares of Poxel was 51.43 M in 2025. This indicates how many shares Poxel is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
25.95 M Stocks
Jan 1, 2020
28.46 M Stocks
Jan 1, 2021
28.67 M Stocks
Jan 1, 2022
29.19 M Stocks
Jan 1, 2023
31.74 M Stocks
Jan 1, 2024
51.43 M Stocks
Jan 1, 2025 (e)
51.43 M Stocks
Jan 1, 2026 (e)
51.43 M Stocks

Current Poxel forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
88.89 % (8)
Hold
11.11 % (1)
Sell
0.00 % (0)
12M Price Target
3.57
Last Price
0.20
Currency
EUR
12M Return Potential
1,662.96 %
LTM Return
0 %

Poxel Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
2/14/2023-0.21EUR--EUR-2022 Q4
9/21/2022-0.63EUR--EUR-2022 Q2

EESG©

Eulerpool ESG Scorecard© for the Poxel stock

60/100
18
Environment
99
Social
63
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy1.78
Scope 3 - Indirect emissions within the value chain40
Total CO₂ emissions1.78
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees69
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Poxel shareholder structure

% Name
4.98981%
Bpifrance Participations S.A.
Bpifrance Participations S.A.
3.29812%
Kuhn (Thomas)
Kuhn (Thomas)

Poxel Beneficial Ownership Filings (SEC 13D/G)

Free Float
77.8%
Float Shares
-
Shares Outstanding
-

Poxel Executives and Management Board

12 members · avg. age 55 · 42 % women

Management

NT

Mr. Nicolas Trouche

Chief Executive Officer, Director · since 2025

–
SB

Dr. Sebastien Bolze

Chief Operating Officer, Executive Vice President in charge of Project Management, Non Clinical and Manufacturing operations · since 2019

–
NB

Mr. Noah Beerman (55)

Executive Vice President in charge of Business Development and President of Operations in the United States

–
PF

Dr. Pascale Fouqueray

Executive Vice President, in charge of Clinical Development and Regulatory Affairs · since 2019

–
EW

Ms. Elizabeth Woo

Senior Vice President, Investor Relations, Public Relations and Corporate Communications

–
SB

Dr. Sophie Bozec

Senior Vice President in charge of R&D Pharmacology and Scientific Communication · since 2019

–

Board of Directors

SL

Ms. Sophie Lapointe

Independent Chairman of the Board

–
AB

Mr. Alexandre Bragadir

Director

–
AK

Mr. Amit Kohli

Independent Director

–

Poxel Supply Chain

Poxel Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
3 companies
#NameTrend
1
Sumitomo Pharma
Supplier·Customer·Pharmaceuticals·JP
-0.64
0.12
0.36
0.84
0.86
0.44
#NameTrend
1
Roivant Sciences
Supplier·Customer·Pharmaceuticals·GB
0.35
0.15
0.88
0.85
0.82
—
2
Merck
Supplier·Customer·Pharmaceuticals·DE
0.11
0.30
0.08
0.83
-0.04
-0.53

Frequently asked questions about Poxel

The business model of Poxel SA revolves around the development and commercialization of innovative drugs to treat metabolic disorders. Poxel SA focuses on the discovery and development of safe and effective therapeutic solutions for diseases such as type 2 diabetes and non-alcoholic steatohepatitis (NASH). By leveraging their expertise in mitochondrial metabolism, the company aims to offer advanced treatment options to patients worldwide. Poxel SA also seeks to collaborate with strategic partners and leverage their partnerships to advance the development of its product portfolio. Through its dedicated efforts, Poxel SA strives to improve the lives of individuals affected by metabolic disorders.

Poxel SA is primarily active in the pharmaceutical industry.

The main competitors of Poxel SA in the market include pharmaceutical companies such as Novo Nordisk, Sanofi, and Eli Lilly.

Poxel SA is a pharmaceutical company specializing in the development of innovative treatments for metabolic diseases. Founded in 2009, the company is headquartered in Lyon, France. Poxel focuses on developing drugs that address unmet medical needs in areas such as type 2 diabetes and non-alcoholic steatohepatitis (NASH). The company's research and development efforts are supported by a robust pipeline and collaborations with renowned academic institutions and strategic partners. Poxel's mission is to improve the lives of patients worldwide by providing effective therapeutic solutions. With its commitment to scientific excellence and patient-centric approach, Poxel is at the forefront of advancing treatments for metabolic diseases.

Poxel SA, a renowned French biopharmaceutical company, has accomplished significant milestones in its journey. Notably, Poxel SA successfully completed the Phase 3 trials for its lead product, Imeglimin, a potential groundbreaking treatment for type 2 diabetes. Additionally, the company received positive feedback from regulatory authorities, advancing its development plans globally. Furthermore, Poxel SA secured strategic partnerships and collaborations with esteemed organizations to enhance its research and development efforts. These achievements demonstrate Poxel SA's dedication to revolutionizing healthcare through innovative therapies.

Poxel SA is primarily present in various countries and regions worldwide. The company has a strong presence in Europe, with a focus on France, Germany, and Italy. Additionally, Poxel SA operates in North America, particularly in the United States. The company also has a presence in Asia, with key markets including Japan and South Korea. With its global outreach, Poxel SA is constantly expanding its geographical footprint to reach more markets and serve a broader customer base.

Poxel SA represents a strong set of values and corporate philosophy. The company is committed to driving innovation and advancing scientific research in the field of metabolic disorders. Poxel SA prioritizes integrity, professionalism, and collaboration, which are embodied in its dedicated team and partnerships. With a focus on patient-centricity, Poxel SA strives to develop effective treatments for serious conditions like type 2 diabetes and non-alcoholic steatohepatitis. By leveraging its expertise and leveraging cutting-edge technologies, Poxel SA aims to make a positive impact on patients' lives worldwide.

Analysts currently set an average price target of 3.57 EUR for the Poxel stock (median: 3.57 EUR), implying +1,663.0 % versus the latest price. The consensus is based on 9 analyst ratings.

Poxel Analyst Price Targets 2026

9 analysts currently rate the Poxel stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Poxel to generate revenue of 39.27 M EUR and earnings per share of -1.82 EUR.

Poxel Analyst Price Targets 2026

The Poxel share (POXEL.PA) is listed on 6 stock exchanges, including: Frankfurt (7PO.F), München (7PO.MU), London (0RA2.L), Paris (POXEL.PA).

Poxel SA is a French biopharmaceutical company focused on developing and marketing groundbreaking therapeutics for the treatment of metabolic diseases. The company collaborates closely with prominent academic institutions and research facilities worldwide to develop innovative solutions aimed at improving patients' quality of life. The company offers a wide range of products, including Imeglimin, a novel molecule that improves mitochondrial function and increases insulin sensitivity in the body. Imeglimin aims to treat type 2 diabetes and other metabolic diseases by directly acting on the insulin sensitivity of cells. Another important product of Poxel SA is PXL770, a small molecule that stimulates the AMPK signaling pathway. This improves insulin sensitivity and can help combat obesity and other metabolic diseases. The company has also entered into a collaboration with Roivant Sciences to develop a treatment program for non-alcoholic steatohepatitis (NASH). This involves testing a compound called PXL065, which is intended to act in the liver and could help reduce inflammation and fibrosis. To finance the development and marketing of these products, Poxel SA utilizes a unique business model that is based on collaboration with strategic partners, as well as clinical studies and licenses. The company works closely with leading players in the pharmaceutical industry to develop and market its products. Through licensing agreements and the sale of research and development to partner companies, the company can bring its products to market and simultaneously finance its research and development activities. Furthermore, Poxel SA employs innovative business models to accelerate the development and marketing of its products. The company is heavily involved in the research and development efforts of its partners, utilizing state-of-the-art scientific methods and technologies. The company also collaborates closely with academic institutions and research facilities to develop new therapies and technologies targeting metabolic diseases. Overall, Poxel SA is an innovative company focused on the development and marketing of metabolic therapies. Through collaboration with other pharmaceutical companies and academic institutions, the company is able to bring its products to market, finance its research and development, and improve the quality of life for patients worldwide.

The expected revenue of Poxel is 39.27 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Poxel is -93.51 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Poxel is currently -0.11. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Poxel stock.

The price-to-sales ratio (P/S) of Poxel is currently 0.26. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Poxel stock.

The Eulerpool Quality Score for Poxel is 2/10.

The ISIN of Poxel is FR0012432516. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Poxel is A14M04. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Poxel is POXEL.PA. The ticker symbol is used to trade Poxel shares on the stock exchange.

Poxel paid dividends every year for the past 0 years.

Poxel is assigned to the 'Health' sector.

The dividends of Poxel are distributed in EUR.

All fundamentals and in-depth analysis of Poxel

Our stock analysis for Poxel stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Poxel. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Poxel Stock
Poxel Revenue→
Poxel Stock
Poxel Net Income→
Poxel Stock
Poxel P/E→
Poxel Stock
Poxel P/S→
Poxel Stock
Poxel EBIT→
Poxel Stock
Poxel Dividend→
Poxel Stock
Poxel Directors Dealings→
Poxel Stock
Poxel Stocks→
Poxel Stock
Poxel Market capitalization→
Poxel Stock
Poxel Debt→
Poxel Stock
Poxel Liabilities→
Poxel Stock
Poxel Equity→
Poxel Stock
Poxel AAQS→
Poxel Stock
Poxel Employees→
Poxel Stock
Poxel ROE→
Poxel Stock
Poxel ROA→
Poxel Stock
Poxel ROCE→
Poxel Stock
Poxel News→
Poxel Stock
Poxel Analyst Price Targets→

Health Stocks

PPJ Healthcare EnterprisesPositronPraram 9 Hospital PCLPorton Pharma SolutionsPraxis Precision MedicinesPoolbeg PharmaPrecigenPoniard PharmaceuticalsPrecipioPOMDOCTOR LIMITED American Depositary SharesPrecision BioSciencesPolyrizonAll Stocks A–Z →